Skip to main content
    M

    Molecular Partners AG ADR (MOLN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.77
    +0.07 (+2.65%)

    Market Cap: $112.71M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Molecular Partners AG ADR (MOLN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Molecular Partners AG ADR (MOLN) has a market cap of $112.71M. It earned CHF -54.19M on revenue of CHF 0 over the last 12 months.

    Total Valuation

    Market Cap$112.71M
    Latest price (Nov 17, 2026)$2.77

    Key Dates

    Last Earnings DateOct 29, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 1.19% in the quarter ended Sep 30, 2026 and grew 7.45% a year over 2 years.

    Shares Outstanding38.33M
    Shares Change (YoY)+2.48%
    Shares Change (QoQ)-1.19%
    Share Count Growth (2Y CAGR)+7.45%

    Price Statistics

    The stock is down 34.36% over 52 weeks and trades 24.93% below its 50-day average.

    Beta (1Y)0.56
    52-Week Change-34.36%
    1-Month Change-24.32%
    3-Month Change-36.03%
    6-Month Change-25.94%
    5-Year Change-80.76%
    Total Return (1Y)-34.36%
    Total Return (3Y CAGR)-13.90%
    Total Return (5Y CAGR)-22.64%
    Return vs SPY (1Y)-44.33%
    Max Drawdown (1Y)-47.34%
    Max Drawdown (3Y)-75.49%
    Sharpe Ratio (1Y)-0.77
    Correlation with SPY (1Y)0.15
    50-Day Average$3.69
    200-Day Average$4.11
    52-Week Range$2.63 to $5.36
    RSI (14 Days)27.1
    Average Volume (20 Days)2.08K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.46x current liabilities.

    Current Ratio6.46x
    Quick Ratio6.46x
    Interest Coverage-1462.23x

    Returns and Efficiency

    Return on equity is -110.77% over the last 12 months, against a 5-year average of -31.87%.

    Return on Equity (ROE)-110.77%
    Return on Assets (ROA)-86.98%
    ROE (5Y Average)-31.87%
    ROA (5Y Average)-23.54%
    ROIC (5Y Average)-31.29%

    Scores

    MOLN has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was CHF 0 over the last 12 months.

    RevenueCHF 0
    Gross ProfitCHF -22.63M
    Operating IncomeCHF -54.89M
    Pretax IncomeCHF -54.18M
    Net IncomeCHF -54.19M
    EBITDACHF -52.12M

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 78.52% of the CHF 64.52M in total assets.

    Working CapitalCHF 51.32M
    Shareholder EquityCHF 50.66M
    Total AssetsCHF 64.52M
    Total LiabilitiesCHF 13.85M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash FlowCHF -49.24M
    Depreciation and AmortizationCHF 2.11M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About MOLN

    What is MOLN's market cap?

    Molecular Partners AG ADR has a market cap of $112.71M.

    How many shares of MOLN are outstanding?

    Molecular Partners AG ADR has 38.33M shares outstanding. The count is up 2.48% from a year earlier.

    Does MOLN pay a dividend?

    No. Molecular Partners AG ADR does not pay a dividend.